ArticleDiscover oncology2025
Transformation and survival in patients with Waldenström macroglobulinemia: a population-based study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWaldenström's macroglobulinemia (WM) is a rare hematologic neoplasm characterized by an indolent clinical course. However, a significant proportion of patients undergo histological transformation to aggressive diffuse large B-cell lymphoma (DLBCL). Long-term population-based data on the transformation and survival are scarce. Based on the Surveillance, Epidemiology, and End Results (SEER) database, we performed this study to estimate the risk of transformation and outcomes of patients with WM.
methods8191 patients with WM were retrieved from the SEER database. Competing risk methods were employed to evaluate the cumulative incidences and putative risk factors for transformation. Survival outcomes were analyzed using Kaplan-Meier and Cox proportional hazards regression.
resultsThe cumulative incidence rates for transformation at 5 and 10 years were 1.0% (95% CI, 0.8%-1.3%) and 1.9% (95% CI, 1.5%-2.2%), respectively. A substantial increase in total mortality was related to the time-dependent transformation (HR, 4.21 [95% CI, 3.36-5.26]; P < 0.001). Patients who presented with transformation > 24 months after WM diagnosis had a longer overall survival (OS) than those who experienced transformation within 24 months (5-year rate, 81.9% [95% CI, 74.7%-89.9%] v 42.7% [95% CI, 26.4%-69.2%]; P < 0.001). The OS was shorter for patients with DLBCL transformed from WM than for those with matched de novo DLBCL (5-year rate, 28.0% [95% CI, 20.5%-38.1%] v 49.5% [95% CI, 41.2%-59.4%]; P = 0.001).
conclusionsHistological transformation to DLBCL was associated with significantly increased mortality in patients with WM, and the survival outcomes substantially worse than matched de novo DLBCL cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.